drugset / Trial / NCT01238185

Aspirin Mouthwash in Treating Patients With Oral Leukoplakia

NCT01238185

Open-labelTreatment

Summary

RATIONALE: Aspirin mouthwash may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of aspirin mouthwash in treating patients with oral leukoplakia.

Timeline

Start
2010-02
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 75 mg Topical
Subject Aspirin Small molecule 150 mg Topical
Subject Aspirin Small molecule 300 mg Topical

Indications